Roche will invest up to $550 million in its Indianapolis diagnostics site by 2030 to expand production of its continuous glucose monitoring systems.
The Indianapolis location serves as the headquarters for Roche Diagnostics and currently produces 5.2 billion diabetes test strips each year. The site also functions as a distribution hub, supporting the U.S. and 53 other countries, according to a May 12 news release from the company.
The investment is aimed at meeting growing demand for diabetes management tools, and the expansion will include a new CGM manufacturing facility, which is expected to create hundreds of manufacturing jobs and thousands of construction jobs.
The move is part of Roche’s broader effort to strengthen its domestic operations, which has driven more than $800 million in investments at its U.S. sites since 2015.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.